Clinical Investigation to Assess the Effect of Betaglucan Administration in HPV Patients

Vitae Health Innovation

Status

Completed

Conditions

HPV

Treatments

Dietary Supplement: 1000 mg Betaglucans (daily)

Study type

Interventional

Funder types

Industry

Identifiers

NCT06987396

VITAE HEALTH INNOVATION S.L.

Details and patient eligibility

About

Randomised, controlled clinical study to assess the efficacy and tolerability of an oral supplementation of 1000 mg daily of Betaglucans in the evolution of patients with Human Papilloma Virus (HPV). The improvement is measured by DNA PCR test, cytology and a specific RNA test.

Enrollment

80 patients

Sex

Female

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women over 30 years old, whether or not they have been vaccinated against HPV
Patients attending a visit with a routine cytological result of ASCUS or lSIL, or a normal result with a positive HPV test, no more than 3 months prior to be enrolled
Patients who freely provide written informed consent
Patients with a positive DNA PCR test

Exclusion criteria

Patients who are participating in another clinical study about the same or different condition within the 30 days prior to inclusion.
Any subject who, in the investigator's opinion, is unable to follow instructions or properly comply with the treatment.
Subjects who do not provide written informed consent to participate in the study.
Patients who are receiving any of the prohibited drugs or supplements, and for whom withdrawal of these medications/products is expected to pose a significant issue.
Pregnant or breastfeeding women.
Transplanted patients and/or patients taking immunosuppressive medication.
Patients with autoimmune diseases.